Jiangsu Nhwa Pharmaceutical Co., Ltd. Class ASZSE: 002262

Jiangsu Nhwa Pharmaceutical: Q1 2025 net profit up 13.35% year-over-year on strong sales and investment returns

· Issued by Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

Q1 2025 revenue grew 11.29% and net profit rose 13.35% year-over-year, driven by strong sales, higher investment income, and robust cash flow. R&D and management expenses increased, reflecting ongoing investment in growth and innovation.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

All Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A news releases